Sun Pharma Advanced Research Company halts Parkinson's disease drug trial

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-04-10 09:12 GMT   |   Update On 2024-04-10 09:12 GMT
Advertisement

Mumbai: Sun Pharma Advanced Research Company Ltd. (SPARC) today announced results of interim analysis from the PROSEEK study, a global, randomised, double blind, placebo-controlled Phase 2 study in patients with Early Parkinson’s Disease.

PROSEEK compared two doses of Vodobatinib with placebo and enrolled a total of 513 patients from US, Europe and India. The interim analysis was based on data from 442 patients who completed 40 weeks treatment in Part I of the study. The study failed to demonstrate superiority of Vodobatinib in the prespecified primary endpoint of change in MDS-UPDRS Part III total score as compared to placebo.

Read also: SPARC concludes enrolment in global Phase 2 study of Vodobatinib in early Parkinson's disease

SPARC has reviewed the data and determined that the study has not shown evidence of treatment benefit in patients receiving Vodobatinib, and consequently decided to close the study. SPARC plans to complete the full analysis of clinical outcomes and correlative biomarker data in the coming months.

Vodobatinib is a selective, brain penetrant c-Abl inhibitor, being evaluated in Parkinson’s disease, Lewy Body Dementia and Chronic Myelogenous Leukemia.

Read also: SPARC enters into an exclusive worldwide license agreement with Johns Hopkins University, IOCB for hair loss drug

Anil Raghavan, CEO of SPARC commented, "While the interim analysis results were not what we aspired for our patients, the findings from this study will significantly contribute towards expanding the understanding of the role of c-Abl kinase in alpha synucleinopathies. Our gratitude extends to all those who played a role in the PROSEEK study, particularly the patients and their caregivers, researchers, and our dedicated team that worked relentlessly on the study.”

Sun Pharma Advanced Research Company Limited (SPARC) is a clinical-stage biopharmaceutical company. SPARC was formed in 2007 after a demerger from Sun Pharmaceutical Industries Limited. At SPARC, therapeutic focus is in the area of oncology, neurodegeneration and immunology, three critical fields that pose significant challenges in healthcare.

SPARC is a dynamic innovation community with a geographic presence in two countries – US and India, and offices situated in 3 locations of Mumbai, Vadodara and Princeton. Its research facility at Vadodara is spread over 46000 sq.ft. with 42 labs housing 200+ scientists.

Read also: SPARC announces retirement of Dr Chitturi Trinadha Rao - Senior Vice President, Drug Discovery

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News